文献速递甲状腺疾病

局部晚期甲状腺癌的新辅助治疗:拉丁美洲初步经验

Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience.
PubMed 文献 · Thyroid · 2024-06-03

这项回顾性多中心病例系列纳入五个拉丁美洲转诊中心连续接受新辅助全身治疗的局部晚期甲状腺癌患者27例,评估治疗前后肿瘤缓解、手术可行性与切除完整性。新辅助治疗获得肿瘤缓解,但手术可行性在分化型甲状腺癌为55%、未分化癌为33%、髓样癌为16%,全队列R0/R1切除率为26%。

要点

  • 27例局部晚期甲状腺癌患者接受新辅助靶向治疗,中位年龄66岁,52%为女性。
  • 分化型/低分化甲状腺癌原发肿瘤中位缩小25%,55%可手术,其中60%达R0/R1。
  • 髓样癌中位缩小24.5%、未分化癌中位缩小42%;全队列R0/R1切除率26%。

核心结论

  • 新辅助治疗虽获得肿瘤缓解,但手术可行性在分化型甲状腺癌为55%、未分化癌为33%、髓样癌为16%,全队列R0/R1切除率为26%,作者强调需筛选患者并进一步研究。

研究设计与样本

  • 回顾性多中心病例系列,纳入五个拉丁美洲转诊中心连续接受新辅助全身治疗的局部晚期甲状腺恶性肿瘤患者,共27例。

主要发现

  • 不可切除的分化型甲状腺癌或低分化甲状腺癌患者接受索拉非尼(n=6)或仑伐替尼(n=12)。
  • 髓样癌患者接受凡德他尼(n=5)或塞尔帕替尼(n=1)。
  • 携带BRAFV600E突变的未分化甲状腺癌患者(n=3)接受达拉非尼联合曲美替尼。
  • 分化型/低分化甲状腺癌原发肿瘤中位治疗6个月后直径中位缩小25%(范围0-100%),10例(55%)接受手术,其中6例(60%)达R0/R1切除。
  • 髓样癌中位治疗9.5个月后肿瘤直径中位缩小24.5%(范围1-49);未分化癌中位治疗2个月后肿瘤直径中位缩小42%(范围6.7-50)。

关键数值与推荐

  • 缓解评估采用实体瘤疗效评价标准(Response Evaluation Criteria in Solid Tumors)。
  • 主要结局为治疗前后缓解评估、手术可行性与切除完整性;次要结局为死亡率和末次访视状态。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Surgical resection is not always achievable in thyroid cancer patients. Neoadjuvant therapy is rarely used, but recent trends favor multikinase inhibitors or selective tyrosine kinase inhibitors. These aim to reduce tumor volume, enabling previously unfeasible surgeries. Patients and Methods: Consecutive patients with locally advanced malignant thyroid tumors who received systemic therapies with a neoadjuvant intention were included in this retrospective multicenter case series conducted in five Latin American referral centers. Primary outcomes were pre- versus postneoadjuvant response evaluations using the Response Evaluation Criteria in Solid Tumors, feasibility of surgery, and completeness of resection. Secondary outcomes were mortality and status at the last visit. Results: Twenty-seven patients were included in this analysis. Patients with unresectable differentiated thyroid cancer (DTC) or poorly differentiated thyroid cancer (PDTC) received sorafenib (n = 6) or lenvatinib (n = 12), those with medullary thyroid cancer (MTC) were treated with vandetanib (n = 5) or selpercatinib (n = 1), and those with anaplastic thyroid cancer (ATC) harboring a BRAFV600E mutation (n = 3) received dabrafenib and trametinib. The median patient age was 66 years (range 12-82), and 52% of the patients were female. In patients with PTC and PDTC, the median reduction in the diameter of the primary tumor was 25% (range 0-100%) after a median of 6 months of treatment. Surgical intervention was performed in 10 (55%) of the patients. Among these, six patients (60%) achieved R0/R1 resection status. Six patients with MTC had a median reduction in tumor diameter of 24.5% (range 1-49) after a median treatment time of 9.5 months. Only one patient receiving selpercatinib, with a tumoral reduction of 25% could undergo surgery, resulting in an R2 resection due to extensive mediastinal extension. Three patients with ATC showed a median tumor diameter reduction of 42% (range 6.7-50) after a median treatment time of 2 months. Two patients underwent surgical intervention and achieved R1 and R2 resection, respectively. Conclusions: While neoadjuvant therapy achieved tumoral responses, surgical resection was feasible in 55% of DTC, 33% of ATC, and 16% of MTC patients, with R0/R1 resection in 26% of the cohort, underscoring the need for patient selection and further research in this area.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Pitoia F, Abelleira E, Román-González A, et al. Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience. Thyroid. 2024. PMID: 38757613. doi:10.1089/thy.2024.0090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。